BioSpace News Archive

--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count--

- PRGN-3006 has been safe and well-tolerated to date - - Case study demonstrated persistence of PRGN-3006 administered without prior lymphodepletion in blood at seven months post-infusion and reduction in blood and bone marrow blasts - - Milestone marks a global first report of direct infusion of non-expanded CAR-T cells leading to in vivo expansion and long-term persistence in patients -

AscellaHealth, a national specialty pharmacy benefit manager serving commercial, Medicare and Medicaid segments, forecasts the overriding trend in 2021 among employers, third party administrators and payers will be the adoption of a specialty pharmacy Rx and/or medical benefit carve-out program that designates one vendor management model across the medical and/or pharmacy benefit channel.

- Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted for presentation at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020) - Investor conference call and webcast scheduled for today, December 7, at 10:00 a.m. ET (7:00 a.m. PT)

Seagen Announces Multiple ADCETRIS ® (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting - Five-Year Update of the ECHELON-1 Clinical Trial Shows Treatment with ADCETRIS in Combination with AVD Chemotherapy Results in Superior Long-Term Outcomes when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma -

Less than 1% of patients treated with CALQUENCE discontinued treatment due to cardiac adverse events in pooled analysis

Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) announce that preliminary data from firstMIND, the ongoing Phase 1b, open-label, randomized study on the safety and efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) were presented today during the 62nd American Society of Hematology Annual Meeting & Exposition

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today presented clinical data on its BTK inhibitor BRUKINSA® (zanubrutinib) in two posters at the 62nd American Society for Hematology (ASH) Annual Meeting

Liso-cel elicited high overall response rates in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma both as monotherapy and in combination with ibrutinib, and rapid, deep and durable responses were observed with the longer-term follow-up monotherapy treated cohort in TRANSCEND CLL 004 1,2 Preliminary results from TRANSCEND NHL 001 cohort evaluating liso-cel in relapsed or refractory mantle cell lymphoma showed high r

Walgreens Boots Alliance, Inc. announced the retirement plans of Executive Vice President and Global Chief Human Resources Officer Kathleen Wilson-Thompson and announced Pamela Puryear, Ph.D., as her successor.